{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016137","form_type":"8-K","ticker":"OSUR","cik":"0001116463","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.020607+00:00","generated_at":"2026-06-24T01:47:02.280386+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OraSure Q2 revenue record $80.2M (+39% YoY) but GAAP EPS ($0.26); InteliSwab sales surge 95% QoQ","bullets":["GAAP net loss of $18.8M vs. $1.4M loss in Q2 2021; gross margin fell to 34.4% from 53.2%.","Non-GAAP gross margin improved 250 bps sequentially to 40.1%; non-GAAP EPS ($0.00).","Q3 revenue guidance $90-95M (67-76% YoY growth); expects positive cash flow by Q4 2022.","Appointed Ken McGrath as CFO effective Aug 8; three directors resign Nov 8; Mara Aspinall to become Board Chair.","InteliSwab capacity now ~1.6M tests/week, expected to nearly double by early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016137","json":"https://secwatch.observer/filing/0000950170-22-016137.json","markdown":"https://secwatch.observer/filing/0000950170-22-016137.md","text":"https://secwatch.observer/filing/0000950170-22-016137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022016137/0000950170-22-016137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000095017022016137/osur-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:47:02.280386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}